Imperial Innovations has led a £50m series-B funding round for UK biotech Cell Medica alongside Invesco Perpetual and Woodford Investment Management.
Deal includes three manufacturing facilities located in Spain, which employ around 140 staff
GP acquired the care home group from Swiss Prime Site and will be the company's sole shareholder
Iris, Idinvest and historical backers invest in the manager of the eponymous social media app
GP uses its Mérieux Participations 3 fund, which held a first close on €200m in 2018